This Day On The Street
Continue to site
ADVERTISEMENT
This account is pending registration confirmation. Please click on the link within the confirmation email previously sent you to complete registration.
Need a new registration confirmation email? Click here

Cancer Vaccines: From First-in-Class To Best-in-Class?

1.2 List of Tables

Table 1: Cancer Highlights' Five Pillar Drug Assessment 7Table 2: Breakdown of the Included Cancer Vaccine Drug Pipeline by Stage of Development 28Table 3: Head to Head Target Competition among Cancer Vaccine Drugs 28Table 4: Overview of Drug Target Strategy Themes 33Table 5: Ceased Targets of Cancer Vaccine Drugs 34Table 6: Official Gene Symbol to Target Profle 35Table 7: Mutation Frequencies of Cancer Vaccine Drug Targets 202Table 8: Number of Target-Target Interactions among Targets of Cancer Vaccine Drugs 206Table 9: Available Protein Expression Profiles of Cancer Vaccine Drug Targets 208Table 10: Pathway Summary 216Table 11: Drug Targets without any Identified Assigned Pathways 216Table 12: Pathway Profiles According to BioCarta of Cancer Vaccine Drug Targets 218Table 13: Pathway Profiles According to KEGG of Cancer Vaccine Drug Targets 226Table 14: Pathway Profiles According to NetPath of Cancer Vaccine Drug Targets 243Table 15: First-in-Class Analysis of Drug Target Strategies 247Table 16: Top Competitive Target Strategies of Cancer Vaccine Drugs 247Table 17: First-in-Class and Me-too of Cancer Vaccine Drugs being Marketed 249Table 18: First-in-Class and Me-too of Cancer Vaccine Drugs in Phase III Clinical 250Table 19: The Competition Through Close Mechanistic Approximation Between Phase III Cancer Vaccine Drugs 251Table 20: First-in-Class and Me-too of Cancer Vaccine Drugs in Phase II Clinical Development 252Table 21: The Competition Through Close Mechanistic Approximation Between Phase II Cancer Vaccine Drugs 254Table 22: First-in-Class and Me-too of Cancer Vaccine Drugs in Phase I Clinical Development 255Table 23: The Competition Through Close Mechanistic Approximation Between Phase I Cancer Vaccine Drugs 257Table 24: First-in-Class and Me-too of Cancer Vaccine Drugs in Preclinical Development 258Table 25: The Competition Through Close Mechanistic Approximation Between Preclinical Cancer Vaccine Drugs 259Table 26: Target Strategies of No Data, Suspended or Terminated Cancer Vaccine Drugs 261Table 27: Finding Competitive Profile for Best-in-Class Consideration 263Table 28: Overview of Compound Strategy Competition Among Cancer Vaccine Drugs 388Table 29: Overview of the Competitive Landscape of Small Molecule Based Cancer Vaccine Drugs 390Table 30: Pursued Target Strategies of Small Molecule Drugs Based Cancer Vaccine Drugs 391Table 31: Overview of the Competitive Landscape of Peptide Based Cancer Vaccine Drugs 393Table 32: Competitive Comparison of Target Strategies of Peptide Based Cancer Vaccine Drugs 394Table 33: Pursued Target Strategies of Peptide Based Cancer Vaccine Drugs 395Table 34: Overview of the Competitive Landscape of Protein Based Cancer Vaccine Drugs 397Table 35: Competitive Comparison of Target Strategies of Protein Based Cancer Vaccine Drugs 398Table 36: Pursued Target Strategies of Protein Based Cancer Vaccine Drugs 398Table 37: Overview of the Competitive Landscape of Antibody Based Cancer Vaccine Drugs 400Table 38: Competitive Comparison of Target Strategies of Antibody Based Cancer Vaccine Drugs 401Table 39: Pursued Target Strategies of Antibody Based Cancer Vaccine Drugs 401Table 40: Overview of the Competitive Landscape of Nucleic Acid Based Cancer Vaccine Drugs 404Table 41: Competitive Comparison of Target Strategies of Nucleic Acid Based Cancer Vaccine Drugs 405Table 42: Pursued Target Strategies of Nucleic Acid Based Cancer Vaccine Drugs 405Table 43: Potential Forms of Cell Therapy 407Table 44: Vectors in Gene Therapy 408Table 45: Overview of the Competitive Landscape of Cell Therapy Based Cancer Vaccine Drugs 408Table 46: Competitive Comparison of Target Strategies of Cell Therapy Based Cancer Vaccine Drugs 409Table 47: Pursued Target Strategies of Cell Therapy Based Cancer Vaccine Drugs 409Table 48: Overview of the Competitive Landscape of Gene Therapy Based Cancer Vaccine Drugs 410Table 49: Competitive Comparison of Target Strategies of Gene Therapy Based Cancer Vaccine Drugs 411Table 50: Pursued Target Strategies of Gene Therapy Based Cancer Vaccine Drugs 412Table 51: The Competition Through Close Mechanistic Approximation Among Cancer Vaccine Drugs 414Table 52 Competitive Summary by Indication of Cancer Vaccine Drugs 418Table 53: Target Strategy Development Profiles of Cancer Vaccine Drugs for the Treatment of Acute Lymphocytic Leukemia 420Table 54: Target Strategy Development Profiles of Cancer Vaccine Drugs for the Treatment of Acute Myelogenous Leukemia 421Table 55: The Competition through Close Mechanistic Approximation between Acute Myelogenous Leukemia Drugs 421Table 56: Target Strategy Development Profiles of Cancer Vaccine Drugs for the Treatment of Acute Promyelocytic Leukemia 423Table 57: Target Strategy Development Profiles of Cancer Vaccine Drugs for the Treatment of Anal Dysplasia 424Table 58: Target Strategy Development Profiles of Cancer Vaccine Drugs for the Treatment of B-cell Lymphoma 425Table 59: Target Strategy Development Profiles of Cancer Vaccine Drugs for the Treatment of Biliary Cancer 426Table 60: Target Strategy Development Profiles of Cancer Vaccine Drugs for the Treatment of Bladder Cancer 427Table 61: Target Strategy Development Profiles of Cancer Vaccine Drugs for the Treatment of Bone Cancer 428Table 62: Target Strategy Development Profiles of Cancer Vaccine Drugs for the Treatment of Brain Cancer 429Table 63: The Competition through Close Mechanistic Approximation between Brain Cancer Drugs 429Table 64: Target Strategy Development Profiles of Cancer Vaccine Drugs for the Treatment of Breast Cancer 431Table 65: The Competition through Close Mechanistic Approximation between Breast Cancer Drugs 432Table 66: Target Strategy Development Profiles of Cancer Vaccine Drugs for the Treatment of Cancer (general) 434Table 67: Target Strategy Development Profiles of Cancer Vaccine Drugs for the Treatment of Cervical Cancer 435Table 68: The Competition through Close Mechanistic Approximation between Cervical Cancer Drugs 437Table 69: Target Strategy Development Profiles of Cancer Vaccine Drugs for the Treatment of Cervical Dysplasia 438Table 70: The Competition through Close Mechanistic Approximation between Cervical Dysplasia Drugs 439Table 71: Target Strategy Development Profiles of Cancer Vaccine Drugs for the Treatment of Chronic Myelogenous Leukemia 440Table 72: Target Strategy Development Profiles of Cancer Vaccine Drugs for the Treatment of Colorectal Adenoma 441Table 73: Target Strategy Development Profiles of Cancer Vaccine Drugs for the Treatment of Colorectal Cancer 442Table 74: The Competition through Close Mechanistic Approximation between Colorectal Cancer Drugs 443Table 75: Target Strategy Development Profiles of Cancer Vaccine Drugs for the Treatment of Endometrial Cancer 445Table 76: Target Strategy Development Profiles of Cancer Vaccine Drugs for the Treatment of Fallopian Tube Cancer 446Table 77: Target Strategy Development Profiles of Cancer Vaccine Drugs for the Treatment of Gastrointestinal Cancer (general) 447Table 78: Target Strategy Development Profiles of Cancer Vaccine Drugs for the Treatment of Gastrointestinal Stomach Cancer 448Table 79: Target Strategy Development Profiles of Cancer Vaccine Drugs for the Treatment of Glioma 449Table 80: Target Strategy Development Profiles of Cancer Vaccine Drugs for the Treatment of Head and Neck Cancer 450Table 81: The Competition through Close Mechanistic Approximation between Head and Neck Cancer Drugs 450Table 82: Target Strategy Development Profiles of Cancer Vaccine Drugs for the Treatment of Hematological Cancer (general) 452Table 83: Target Strategy Development Profiles of Cancer Vaccine Drugs for the Treatment of Leukemia (general) 453Table 84: Target Strategy Development Profiles of Cancer Vaccine Drugs for the Treatment of Liver Cancer 454Table 85: The Competition through Close Mechanistic Approximation between Liver Cancer Drugs 454Table 86: Target Strategy Development Profiles of Cancer Vaccine Drugs for the Treatment of Lung Cancer (general) 455Table 87: The Competition through Close Mechanistic Approximation between Lung Cancer (general) Drugs 457Table 88: Target Strategy Development Profiles of Cancer Vaccine Drugs for the Treatment of Lymphoma (general) 458Table 89: Target Strategy Development Profiles of Cancer Vaccine Drugs for the Treatment of Melanoma 459Table 90: The Competition through Close Mechanistic Approximation between Melanoma Drugs 460Table 91: Target Strategy Development Profiles of Cancer Vaccine Drugs for the Treatment of Merkel cell carcinoma 462Table 92: Target Strategy Development Profiles of Cancer Vaccine Drugs for the Treatment of Mesothelioma 463Table 93: Target Strategy Development Profiles of Cancer Vaccine Drugs for the Treatment of Myelodysplastic Syndrome 464Table 94: Target Strategy Development Profiles of Cancer Vaccine Drugs for the Treatment of Myeloma 465Table 95: The Competition through Close Mechanistic Approximation between Myeloma Drugs 465Table 96: Target Strategy Development Profiles of Cancer Vaccine Drugs for the Treatment of non-Hodgkin's Lymphoma 466Table 97: Target Strategy Development Profiles of Cancer Vaccine Drugs for the Treatment of Non-Small Cell Lung Cancer 467Table 98: The Competition through Close Mechanistic Approximation between Non-Small Cell Lung Cancer Drugs 468Table 99: Target Strategy Development Profiles of Cancer Vaccine Drugs for the Treatment of Oesophageal Cancer 469Table 100: Target Strategy Development Profiles of Cancer Vaccine Drugs for the Treatment of Osteo Sarcoma 470Table 101: Target Strategy Development Profiles of Cancer Vaccine Drugs for the Treatment of Ovarian Cancer 471Table 102: The Competition through Close Mechanistic Approximation between Ovarian Cancer Drugs 472Table 103: Target Strategy Development Profiles of Cancer Vaccine Drugs for the Treatment of Pancreatic Cancer 473Table 104: The Competition through Close Mechanistic Approximation between Pancreatic Cancer Drugs 474Table 105: Target Strategy Development Profiles of Cancer Vaccine Drugs for the Treatment of Peritoneal Cancer 475Table 106: Target Strategy Development Profiles of Cancer Vaccine Drugs for the Treatment of Prostate Cancer 476Table 107: The Competition through Close Mechanistic Approximation between Prostate Cancer Drugs 477Table 108: Target Strategy Development Profiles of Cancer Vaccine Drugs for the Treatment of Radio/chemotherapy-induced Bone Marrow Injury (general) 479Table 109: Target Strategy Development Profiles of Cancer Vaccine Drugs for the Treatment of Renal Cancer 480Table 110: The Competition through Close Mechanistic Approximation between Renal Cancer Drugs 481Table 111: Target Strategy Development Profiles of Cancer Vaccine Drugs for the Treatment of Sarcoma (general) 482Table 112: Target Strategy Development Profiles of Cancer Vaccine Drugs for the Treatment of Skin Cancer (general) 483Table 113: Target Strategy Development Profiles of Cancer Vaccine Drugs for the Treatment of Small Cell Lung Cancer 484Table 114: Target Strategy Development Profiles of Cancer Vaccine Drugs for the Treatment of Soft Tissue Sarcoma 485Table 115: Target Strategy Development Profiles of Cancer Vaccine Drugs for the Treatment of Solid Tumor 486Table 116: Target Strategy Development Profiles of Cancer Vaccine Drugs for the Treatment of Squamous Cell Carcinoma 487Table 117: Target Strategy Development Profiles of Cancer Vaccine Drugs for the Treatment of T-cell Lymphoma 488Table 118: Target Strategy Development Profiles of Cancer Vaccine Drugs for the Treatment of Thyroid Cancer 489Table 119: Target Strategy Development Profiles of Cancer Vaccine Drugs for the Treatment of Unspecified Cancer Indication 490Table 120: The Competition through Close Mechanistic Approximation between Unspecified Cancer Indication Drugs 491Table 121: Target Strategy Development Profiles of Cancer Vaccine Drugs as Vaccine adjunct 492Table 122: Competitive Summary by Company of Cancer Vaccine Drug Development 493Table 123: Summary Table of Corporate Changes in the Competitive Landscape of Cancer Vaccine Drug Development 496Table 124: The Worst Ranking and the Highest Populated Level for Each of the 15 Ranking Parameters 499Table 125: Example of a Competitive Fall-Out Table (Targeting TERT Modified) 505Table 126: AC Immune's Included Cancer Vaccine Drugs and Competitive Fall-Out 508Table 127: Adaptimmune's Included Cancer Vaccine Drugs and Competitive Fall-Out 512Table 128: Advaxis' Included Cancer Vaccine Drugs and Competitive Fall-Out 518Table 129: Agenus' Included Cancer Vaccine Drugs and Competitive Fall-Out 525Table 130: Aida Pharmaceuticals' Included Cancer Vaccine Drugs and Competitive Fall-Out 529Table 131: AlphaVax's Included Cancer Vaccine Drugs and Competitive Fall-Out 533Table 132: Amgen's Included Cancer Vaccine Drugs and Competitive Fall-Out 539Table 133: Anza Therapeutics' Included Cancer Vaccine Drugs and Competitive Fall-Out 543Table 134: Argos Therapeutics' Included Cancer Vaccine Drugs and Competitive Fall-Out 546Table 135: Astellas' Included Cancer Vaccine Drugs and Competitive Fall-Out 549Table 136: AstraZeneca's Included Cancer Vaccine Drugs and Competitive Fall-Out 552Table 137: Bavarian Nordic's Included Cancer Vaccine Drugs and Competitive Fall-Out 556Table 138: Bellicum Pharmaceuticals' Included Cancer Vaccine Drugs and Competitive Fall-Out 561Table 139: Biogen Idec's Included Cancer Vaccine Drugs and Competitive Fall-Out 565Table 140: BioNTech's Included Cancer Vaccine Drugs and Competitive Fall-Out 568Table 141: BioSante's Included Cancer Vaccine Drugs and Competitive Fall-Out 572Table 142: Biostar's Included Cancer Vaccine Drugs and Competitive Fall-Out 576Table 143: BioVex's Included Cancer Vaccine Drugs and Competitive Fall-Out 579Table 144: BreakThrough Therapeutics' Included Cancer Vaccine Drugs and Competitive Fall-Out 582Table 145: Bristol-Myers Squibb's Included Cancer Vaccine Drugs and Competitive Fall-Out 585Table 146: Cancer Advances' Included Cancer Vaccine Drugs and Competitive Fall-Out 588Table 147: Cancer Research Technology's Included Cancer Vaccine Drugs and Competitive Fall-Out 592Table 148: Celldex Therapeutics' Included Cancer Vaccine Drugs and Competitive Fall-Out 599Table 149: Center of Molecular Immunology's Included Cancer Vaccine Drugs and Competitive Fall-Out 604Table 150: CG Therapeutics' Included Cancer Vaccine Drugs and Competitive Fall-Out 608Table 151: Cosmo Pharmaceuticals' Included Cancer Vaccine Drugs and Competitive Fall-Out 613Table 152: CreaGene's Included Cancer Vaccine Drugs and Competitive Fall-Out 617Table 153: CSL's Included Cancer Vaccine Drugs and Competitive Fall-Out 621Table 154: CureVac's Included Cancer Vaccine Drugs and Competitive Fall-Out 624Table 155: Dainippon Sumitomo Pharma's Included Cancer Vaccine Drugs and Competitive Fall-Out 629Table 156: Dendreon's Included Cancer Vaccine Drugs and Competitive Fall-Out 635Table 157: DeveloGen's Included Cancer Vaccine Drugs and Competitive Fall-Out 642Table 158: Eisai's Included Cancer Vaccine Drugs and Competitive Fall-Out 645Table 159: Eli Lilly's Included Cancer Vaccine Drugs and Competitive Fall-Out 648Table 160: EntreMed's Included Cancer Vaccine Drugs and Competitive Fall-Out 651Table 161: Epeius Biotechnologies' Included Cancer Vaccine Drugs and Competitive Fall-Out 654Table 162: Etubics' Included Cancer Vaccine Drugs and Competitive Fall-Out 659Table 163: Galena Biopharma's Included Cancer Vaccine Drugs and Competitive Fall-Out 667Table 164: Generex's Included Cancer Vaccine Drugs and Competitive Fall-Out 673Table 165: GenOdyssee Pharmaceuticals' Included Cancer Vaccine Drugs and Competitive Fall-Out 678Table 166: Genticel's Included Cancer Vaccine Drugs and Competitive Fall-Out 682Table 167: Geron's Included Cancer Vaccine Drugs and Competitive Fall-Out 686Table 168: GlaxoSmithKline's Included Cancer Vaccine Drugs and Competitive Fall-Out 694Table 169: Gliknik's Included Cancer Vaccine Drugs and Competitive Fall-Out 701Table 170: GlobeImmune's Included Cancer Vaccine Drugs and Competitive Fall-Out 705Table 171: Gradalis' Included Cancer Vaccine Drugs and Competitive Fall-Out 710Table 172: Heat Biologics' Included Cancer Vaccine Drugs and Competitive Fall-Out 713Table 173: Hemispherx Biopharma's Included Cancer Vaccine Drugs and Competitive Fall-Out 716Table 174: Hoffmann-La Roche's Included Cancer Vaccine Drugs and Competitive Fall-Out 719Table 175: Ichor Medical Systems' Included Cancer Vaccine Drugs and Competitive Fall-Out 723Table 176: Idera Pharmaceuticals' Included Cancer Vaccine Drugs and Competitive Fall-Out 728Table 177: immatics biotechnologies' Included Cancer Vaccine Drugs and Competitive Fall-Out 732Table 178: ImmunoCellular Therapeutics' Included Cancer Vaccine Drugs and Competitive Fall-Out 735Table 179: ImmunoFrontier's Included Cancer Vaccine Drugs and Competitive Fall-Out 739Table 180: Immunotope's Included Cancer Vaccine Drugs and Competitive Fall-Out 744Table 181: Immunovaccine's Included Cancer Vaccine Drugs and Competitive Fall-Out 748Table 182: Inovio's Included Cancer Vaccine Drugs and Competitive Fall-Out 752Table 183: Intracel's Included Cancer Vaccine Drugs and Competitive Fall-Out 758Table 184: Introgen Therapeutics' Included Cancer Vaccine Drugs and Competitive Fall-Out 761Table 185: ISA Pharmaceuticals' Included Cancer Vaccine Drugs and Competitive Fall-Out 764Table 186: Jennerex Biotherapeutics' Included Cancer Vaccine Drugs and Competitive Fall-Out 769Table 187: Johnson & Johnson's Included Cancer Vaccine Drugs and Competitive Fall-Out 774Table 188: KAEL-GemVax's Included Cancer Vaccine Drugs and Competitive Fall-Out 778Table 189: Lipotek's Included Cancer Vaccine Drugs and Competitive Fall-Out 782Table 190: Mannkind's Included Cancer Vaccine Drugs and Competitive Fall-Out 786Table 191: MediGene's Included Cancer Vaccine Drugs and Competitive Fall-Out 791Table 192: Menarini's Included Cancer Vaccine Drugs and Competitive Fall-Out 796Table 193: Merck KGaA's Included Cancer Vaccine Drugs and Competitive Fall-Out 800Table 194: Micromet's Included Cancer Vaccine Drugs and Competitive Fall-Out 803Table 195: MolMed's Included Cancer Vaccine Drugs and Competitive Fall-Out 806Table 196: Mologen's Included Cancer Vaccine Drugs and Competitive Fall-Out 809Table 197: Momotaro-Gene's Included Cancer Vaccine Drugs and Competitive Fall-Out 813Table 198: Nemod Biotherapeutics' Included Cancer Vaccine Drugs and Competitive Fall-Out 817Table 199: Neovacs' Included Cancer Vaccine Drugs and Competitive Fall-Out 821Table 200: NIH's Included Cancer Vaccine Drugs and Competitive Fall-Out 825Table 201: Non-industrial source's Included Cancer Vaccine Drugs and Competitive Fall-Out 830Table 202: Northwest Biotherapeutics' Included Cancer Vaccine Drugs and Competitive Fall-Out 839Table 203: NovaRx's Included Cancer Vaccine Drugs and Competitive Fall-Out 842Table 204: OncoMune's Included Cancer Vaccine Drugs and Competitive Fall-Out 845Table 205: OncoTherapy Science's Included Cancer Vaccine Drugs and Competitive Fall-Out 848Table 206: Oncothyreon's Included Cancer Vaccine Drugs and Competitive Fall-Out 852Table 207: Oncovir's Included Cancer Vaccine Drugs and Competitive Fall-Out 859Table 208: Onyvax's Included Cancer Vaccine Drugs and Competitive Fall-Out 862Table 209: Orchestra Therapeutics' Included Cancer Vaccine Drugs and Competitive Fall-Out 865Table 210: Oxford BioMedica's Included Cancer Vaccine Drugs and Competitive Fall-Out 869Table 211: Pepscan Therapeutics' Included Cancer Vaccine Drugs and Competitive Fall-Out 874Table 212: Peptagen's Included Cancer Vaccine Drugs and Competitive Fall-Out 878Table 213: Pfizer's Included Cancer Vaccine Drugs and Competitive Fall-Out 882Table 214: PharmaForm's Included Cancer Vaccine Drugs and Competitive Fall-Out 886Table 215: Pharmexa's Included Cancer Vaccine Drugs and Competitive Fall-Out 891Table 216: Progenics Pharmaceuticals' Included Cancer Vaccine Drugs and Competitive Fall-Out 899Table 217: Protherics' Included Cancer Vaccine Drugs and Competitive Fall-Out 904Table 218: Radient Pharmaceuticals' Included Cancer Vaccine Drugs and Competitive Fall-Out 907Table 219: Receptor BioLogix's Included Cancer Vaccine Drugs and Competitive Fall-Out 911Table 220: responsif's Included Cancer Vaccine Drugs and Competitive Fall-Out 915Table 221: Sanofi's Included Cancer Vaccine Drugs and Competitive Fall-Out 918Table 222: Sarepta Therapeutics' Included Cancer Vaccine Drugs and Competitive Fall-Out 922Table 223: Scancell's Included Cancer Vaccine Drugs and Competitive Fall-Out 926Table 224: Shionogi's Included Cancer Vaccine Drugs and Competitive Fall-Out 929Table 225: TapImmune's Included Cancer Vaccine Drugs and Competitive Fall-Out 932Table 226: Therion Biologics' Included Cancer Vaccine Drugs and Competitive Fall-Out 936Table 227: Transgene's Included Cancer Vaccine Drugs and Competitive Fall-Out 943Table 228: United Biomedical's Included Cancer Vaccine Drugs and Competitive Fall-Out 947Table 229: Vaccinex's Included Cancer Vaccine Drugs and Competitive Fall-Out 950Table 230: Vaxil BioTherapeutics' Included Cancer Vaccine Drugs and Competitive Fall-Out 955Table 231: Vaximm's Included Cancer Vaccine Drugs and Competitive Fall-Out 959Table 232: Vaxon Biotech's Included Cancer Vaccine Drugs and Competitive Fall-Out 963Table 233: Vectura's Included Cancer Vaccine Drugs and Competitive Fall-Out 967Table 234: Vical's Included Cancer Vaccine Drugs and Competitive Fall-Out 971Table 235: Viragen's Included Cancer Vaccine Drugs and Competitive Fall-Out 977Table 236: Virionics' Included Cancer Vaccine Drugs and Competitive Fall-Out 980Table 237: ViroMed's Included Cancer Vaccine Drugs and Competitive Fall-Out 984Table 238: Zensun's Included Cancer Vaccine Drugs and Competitive Fall-Out 988Table 239: Zydus Cadila's Included Cancer Vaccine Drugs and Competitive Fall-Out 992

To order this report: Drug_and_Medication Industry: Cancer Vaccines: From First-in-Class to Best-in-Class?

Contact Clare: clare@reportlinker.com US:(339) 368 6001 Intl:+1 339 368 6001

SOURCE Reportlinker

Copyright 2011 PR Newswire. All rights reserved. This material may not be published, broadcast, rewritten or redistributed.
3 of 3

Check Out Our Best Services for Investors

Action Alerts PLUS

Portfolio Manager Jim Cramer and Director of Research Jack Mohr reveal their investment tactics while giving advanced notice before every trade.

Product Features:
  • $2.5+ million portfolio
  • Large-cap and dividend focus
  • Intraday trade alerts from Cramer
Quant Ratings

Access the tool that DOMINATES the Russell 2000 and the S&P 500.

Product Features:
  • Buy, hold, or sell recommendations for over 4,300 stocks
  • Unlimited research reports on your favorite stocks
  • A custom stock screener
Stocks Under $10

David Peltier uncovers low dollar stocks with serious upside potential that are flying under Wall Street's radar.

Product Features:
  • Model portfolio
  • Stocks trading below $10
  • Intraday trade alerts
14-Days Free
Only $9.95
14-Days Free
To begin commenting right away, you can log in below using your Disqus, Facebook, Twitter, OpenID or Yahoo login credentials. Alternatively, you can post a comment as a "guest" just by entering an email address. Your use of the commenting tool is subject to multiple terms of service/use and privacy policies - see here for more details.
Submit an article to us!
SYM TRADE IT LAST %CHG

Markets

DOW 18,090.18 +52.21 0.29%
S&P 500 2,110.93 +2.01 0.10%
NASDAQ 5,058.6310 -1.6150 -0.03%

Partners Compare Online Brokers

Free Reports

Top Rated Stocks Top Rated Funds Top Rated ETFs